Details of the Drug
General Information of Drug (ID: DMH61ZB)
| Drug Name |
Cimetidine
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Acibilin; Acinil; Altramet; Brumetidina; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidinum; Cimetum; Dyspamet; Edalene; Eureceptor; Evicer; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; Peptol; Sigmetadine; Tagamet; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex; Ci metum; Cimetidine Hcl; Tagamet Hb; Biomet400; C 4522; FPF 1002; SKF 92334; Tagamet Hb 200; CIMETIDINE A/AB; Cimetidina [INN-Spanish]; Cimetidinum [INN-Latin]; DRG-0150; SKF-92334; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); SK&F-92334; Cimetidine (JP15/USP/INN); Cimetidine [USAN:INN:BAN:JAN]; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Indication |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Therapeutic Class |
Antiulcer Agents
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Affected Organisms |
Humans and other mammals
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Structure |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3D MOL | 2D MOL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 252.34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADMET Property |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adverse Drug Reaction (ADR) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical Identifiers |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cross-matching ID | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
 Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Drug Transporter (DTP) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Drug Off-Target (DOT) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Experimental Cancer Drug Sensitivity Information
Drug-Drug Interaction (DDI) Information of This Drug
|
Coadministration of a Drug Treating the Same Disease as Cimetidine
Coadministration of a Drug Treating the Disease Different from Cimetidine (Comorbidity)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
| DIG |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical Formulation |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
| 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1231). | ||||
|---|---|---|---|---|---|
| 2 | Cimetidine FDA Label | ||||
| 3 | BDDCS applied to over 900 drugs | ||||
| 4 | Somogyi A, Gugler R: Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet. 1983 Nov-Dec;8(6):463-95. doi: 10.2165/00003088-198308060-00001. | ||||
| 5 | DPD Approved Drug Products: Cimetidine (200, 300, 400, 600, 800 mg) | ||||
| 6 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
| 7 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
| 8 | ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899. | ||||
| 9 | Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. | ||||
| 10 | Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. | ||||
| 11 | Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. | ||||
| 12 | Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5. | ||||
| 13 | Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34. | ||||
| 14 | Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83. | ||||
| 15 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | ||||
| 16 | Cimetidine induces apoptosis in gastric cancer cells in vitro and inhibits tumor growth in vivo. Oncol Rep. 2010 Mar;23(3):693-700. doi: 10.3892/or_00000686. | ||||
| 17 | Cimetidine induces apoptosis of human salivary gland tumor cells. Oncol Rep. 2007 Mar;17(3):673-8. | ||||
| 18 | Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410. | ||||
| 19 | Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther. 2005 Jan;312(1):144-52. doi: 10.1124/jpet.104.073916. Epub 2004 Sep 13. | ||||
| 20 | Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. doi: 10.1124/mol.106.025890. Epub 2006 May 24. | ||||
| 21 | Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971] | ||||
| 22 | Albin H, Vincon G, Begaud B, Bistue C, Perez P "Effect of aluminum phosphate on the bioavailability of ranitidine." Eur J Clin Pharmacol 32 (1987): 97-9. [PMID: 3582475] | ||||
| 23 | Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931] | ||||
| 24 | Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179] | ||||
| 25 | Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438] | ||||
| 26 | Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261] | ||||
| 27 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
| 28 | Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249] | ||||
| 29 | Gugler R, Jensen JC "Interaction between cimetidine and metronidazole." N Engl J Med 309 (1983): 1518-9. [PMID: 6646177] | ||||
| 30 | Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ. | ||||
| 31 | Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.". | ||||
| 32 | Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS, Shader RI "Clinical importance of the interaction of diazepam and cimetidine." N Engl J Med 310 (1984): 1639-43. [PMID: 6427609] | ||||
| 33 | Somogyi A, Thielscher S, Gugler R "Influence of phenobarbital treatment on cimetidine kinetics." Eur J Clin Pharmacol 19 (1981): 343-7. [PMID: 7238562] | ||||
| 34 | Simons FE, Sussman GL, Simons KJ "Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria." J Allergy Clin Immunol 95 (1995): 685-93. [PMID: 7897151] | ||||
| 35 | Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI "Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam." Psychopharmacology (Berl) 80 (1983): 275-8. [PMID: 6137021] | ||||
| 36 | Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380] | ||||
| 37 | Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388] | ||||
| 38 | Abernethy DR, Greenblatt DJ, Shader RI "Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability." J Pharmacol Exp Ther 229 (1984): 702-5. [PMID: 6726654] | ||||
| 39 | Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL. | ||||
| 40 | Cerner Multum, Inc. "Australian Product Information.". | ||||
| 41 | Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ. | ||||
| 42 | Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747] | ||||
| 43 | Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ. | ||||
| 44 | Galbraith RA, Michnovicz JJ "The effects of cimetidine on the oxidative metabolism of estradiol." N Engl J Med 321 (1989): 269-74. [PMID: 2747769] | ||||
| 45 | Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901] | ||||
| 46 | Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ. | ||||
| 47 | Clyne CA, Estes NA, Wang PJ "Moricizine." N Engl J Med 327 (1992): 255-60. [PMID: 1614466] | ||||
| 48 | Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793] | ||||
| 49 | Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA. | ||||
| 50 | Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
| 51 | Breckenridge AM, Challiner M, Mossman S, et al "Cimetidine increases the action of warfarin in man." Br J Clin Pharmacol 8 (1979): p392-3. [PMID: 508530] | ||||
| 52 | Canadian Pharmacists Association. | ||||
| 53 | Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060] | ||||
| 54 | Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA. | ||||
| 55 | Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA. | ||||
| 56 | Feely J, Wood AJ "Effects of cimetidine on the elimination and actions of ethanol." JAMA 247 (1982): 2819-21. [PMID: 7043008] | ||||
| 57 | Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA. | ||||
| 58 | Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759] | ||||
| 59 | Product Information. Effexor (venlafaxine). Wyeth-Ayerst Laboratories, Philadelphia, PA. | ||||
| 60 | Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD. | ||||
| 61 | Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA. | ||||
| 62 | Mauro VF, Mauro LS, Hageman JH "Alteration of pentoxifylline pharmacokinetics by cimetidine." J Clin Pharmacol 28 (1988): 649-54. [PMID: 3216031] | ||||
| 63 | Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925] | ||||
| 64 | Algozzine GJ, Stewart RB, Springer PK "Decreased clearance of phenytoin with cimetidine." Ann Intern Med 95 (1981): 244-5. [PMID: 7258891] | ||||
| 65 | Dalton MJ, Powell JR, Messenheimer JA Jr, Clark J "Cimetidine and carbamazepine: a complex drug interaction." Epilepsia 27 (1986): 553-8. [PMID: 3757941] | ||||
| 66 | Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231] | ||||
| 67 | Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA. | ||||
| 68 | Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC. | ||||
| 69 | Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL. | ||||
| 70 | Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027] | ||||
| 71 | Blum RA, D'Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7. [PMID: 2012358] | ||||
| 72 | Long CC, Hill SA, Thomas RC, Johnston A, Smith SG, Kendall F, Finlay AY "Effect of terbinafine on the pharmacokinetics of cyclosporin in humans." J Invest Dermatol 102 (1994): 740-3. [PMID: 8176256] | ||||
| 73 | Adachi M, Hinatsu Y, et.al "Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers." Eur J Pharm Sci 76 (2015): 225-30. [PMID: 25988287] | ||||
| 74 | Leighton JA, Bay MK, Maldonado AL, et al "The effect of liver dysfunction on colchicine pharmacokinetics in the rat." Hepatology 11 (1990): 210-5. [PMID: 2307399] | ||||
| 75 | Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770] | ||||
| 76 | Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ. | ||||
| 77 | Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI. | ||||
| 78 | Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC. | ||||
| 79 | Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC. | ||||
| 80 | Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ. | ||||
| 81 | Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ. | ||||
| 82 | Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC. | ||||
| 83 | Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
| 84 | Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA. | ||||
| 85 | Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA. | ||||
| 86 | Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC. | ||||
| 87 | Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL. | ||||
| 88 | Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA. | ||||
| 89 | Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD. | ||||
| 90 | Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY. | ||||
| 91 | Bianchi FM, Cavassini GB, Leo P "Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists." Int J Clin Pharmacol Ther Toxicol 31 (1993): 209-17. [PMID: 8100220] | ||||
| 92 | Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC. | ||||
| 93 | Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
| 94 | Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
| 95 | Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA. | ||||
| 96 | Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
| 97 | Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
| 98 | Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA. | ||||
| 99 | Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069] | ||||
| 100 | Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA. | ||||
| 101 | Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA. | ||||
| 102 | Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
| 103 | Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA. | ||||
| 104 | Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC. | ||||
| 105 | Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316] | ||||
| 106 | Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
| 107 | Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ. | ||||
| 108 | Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
| 109 | Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ. | ||||
| 110 | Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN. | ||||
| 111 | Product Information. Anzemet (dolasetron). Hoechst Marion-Roussel Inc, Kansas City, MO. | ||||
| 112 | Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA. | ||||
| 113 | Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ. | ||||
| 114 | Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH. | ||||
| 115 | Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ. | ||||
| 116 | Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
| 117 | Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA. | ||||
| 118 | Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425] | ||||
| 119 | Bekhti A, Pirotte J "Cimetidine increases serum mebendazole concentrations: implications for treatment of hepatic hydatid cysts." Br J Clin Pharmacol 24 (1987): 390-2. [PMID: 3663452] | ||||
| 120 | Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ. | ||||
| 121 | Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ. | ||||
| 122 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
| 123 | Product Information. Duract (bromfenac). Wyeth-Ayerst Laboratories, Philadelphia, PA. | ||||
| 124 | Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021] | ||||
| 125 | Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA. | ||||
| 126 | Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ. | ||||
| 127 | Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206] | ||||
| 128 | Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA. | ||||
| 129 | Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA. | ||||
| 130 | Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA. | ||||
| 131 | Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
| 132 | Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
| 133 | Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA. | ||||
| 134 | Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL. | ||||
| 135 | Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282] | ||||
| 136 | Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ. | ||||
| 137 | Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN. | ||||
| 138 | Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
| 139 | Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990] | ||||
| 140 | Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447] | ||||
| 141 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||
| 142 | Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880] | ||||
| 143 | Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432] | ||||
| 144 | Product Information. Neutrexin (trimetrexate). US Bioscience, West Conshohocken, PA. | ||||
| 145 | Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL. | ||||
| 146 | Hey JA, Delprado M, Egan RW, Kreutner W "Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects." Ann Allergy Asthma Immunol 76 (1996): 476. [PMID: 8630724] | ||||
| 147 | Bauer LA, Black D, Gensler A "Procainamide-cimetidine drug interaction in elderly male patients." J Am Geriatr Soc 38 (1990): 467-9. [PMID: 2329253] | ||||
| 148 | Pritchett EL, Smith WM, Kirsten EB "Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine." J Clin Pharmacol 28 (1988): 619-24. [PMID: 3063727] | ||||
| 149 | Tjandra-Maga TB, Van Hecken A, Van Melle P, Verbesselt R, de Schepper PJ "Altered pharmacokinetics of oral flecainide by cimetidine." Br J Clin Pharmacol 22 (1986): 108-10. [PMID: 3741720] | ||||